Titlebook: Optimization of Pharmaceutical R&D Programs and Portfolios; Design and Investmen Zoran Antonijevic Book 2015 Springer International Publish

GUAFF

書目名稱Optimization of Pharmaceutical R&D Programs and Portfolios影響因子(影響力)




書目名稱Optimization of Pharmaceutical R&D Programs and Portfolios影響因子(影響力)學(xué)科排名




書目名稱Optimization of Pharmaceutical R&D Programs and Portfolios網(wǎng)絡(luò)公開度




書目名稱Optimization of Pharmaceutical R&D Programs and Portfolios網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Optimization of Pharmaceutical R&D Programs and Portfolios被引頻次




書目名稱Optimization of Pharmaceutical R&D Programs and Portfolios被引頻次學(xué)科排名




書目名稱Optimization of Pharmaceutical R&D Programs and Portfolios年度引用




書目名稱Optimization of Pharmaceutical R&D Programs and Portfolios年度引用學(xué)科排名




書目名稱Optimization of Pharmaceutical R&D Programs and Portfolios讀者反饋




書目名稱Optimization of Pharmaceutical R&D Programs and Portfolios讀者反饋學(xué)科排名

Hyperplasia

cognizant

anarchist

Clinical Aspects of Pharmaceutical Portfolio Managementicially increase or decrease the estimated probability of registration or commercial success. Complex tools, such as including adaptive design principles, and large data software tools can also be utilized to minimize and mitigate the risk and bias embraced by both the R&D and commercial factors

令人心醉

Need for Optimal Design of Pharmaceutical Programs and Portfolios in Modern Medical Product Developmhat these decisions are made at the portfolio level, as individual programs are interdependent. The value of a product depends on quality of product itself, and quality of development program. The value of a portfolio depends on the value of individual products and the strategy for portfolio optimization. Key concepts that are addressed here are:

付出

Zoran AntonijevicAddresses the impact of study design on maximizing the output at the portfolio level in the pharmaceutical industry.Examines portfolio optimization comprehensively by integrating input from multiple s

不知疲倦

978-3-319-34312-9Springer International Publishing Switzerland 2015

LATER

堅毅

Impact of Phase 2b Strategies on Optimization of Drug Development Programswill have a better chance to demonstrate a desirable risk/benefit profile and thus increase the chance of regulatory success and reimbursement by payors. It will also result in improved patient care and greater benefit to society. Multiple papers have been published within industry’s adaptive design working groups, and these are the key findings.

sclera